Treatment of pulmonary exacerbations of cystic fibrosis leads to improved antioxidant status.
Many cystic fibrosis (CF) patients have increased circulating levels of oxidation products and/or decreased antioxidant status. This study investigated whether treatment of pulmonary exacerbations decreased oxidative stress in CF patients. Seventeen adult patients were studied at the beginning and end of treatment with intravenous antibiotics. Plasma concentrations of the antioxidants ascorbic acid, alpha-tocopherol, uric acid and total reduced thiols, together with plasma retinol, lipid hydroperoxides, malondialdehyde and protein carbonyl levels were determined. Median (interquartile range) pretreatment and post-treatment levels were compared using the Wilcoxon signed rank test. Clinical resolution was reflected by improved spirometry. Significant increases were observed in plasma ascorbic acid (pre 30.4 (15.7-38.6) microM, post 35.2 (27.3-49.6) microM), alpha-tocopherol (pre 19.7 (13.6-25.2) microM, post 25.2 (19.3-31.6) microM) and retinol (pre 1.9 (1.5-2.5) microM, post 2.7 (1.7-3.5) microM). No change in plasma total reduced thiols occurred following treatment (pre 409 (366-420) microM, post 392 (366-423) microM), whereas uric acid fell with treatment (pre 307 (274-394) microM, post 260 (216-317) microM). Neither plasma protein carbonyls or malondialdehyde levels altered with treatment (protein carbonyls pre 0.47 (0.28-1.27), post 0.67 (0.42-0.83) nM x mg protein(-1); malondialdehyde pre 0.75 (0.53-1.18), post 0.84 (0.65-1.15) microM). Lipid hydroperoxides levels did decrease following treatment (53 (18-85) versus 17 (10-55) nM). This study demonstrated that treatment of infective exacerbations resulted in increased plasma levels of some antioxidant vitamins. No immediate change in plasma protein oxidation was observed, but lipid oxidation was decreased.
Range
S P
SP
Cystic Fibrosis Unit, Division Respiratory Medicine, Nottingham City Hospital, UK.
Dunster
C
C
Knox
A J
AJ
Kelly
F J
FJ
D000328:Adult; D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D000975:Antioxidants / Q000032:analysis / Q000378:metabolism*; D001205:Ascorbic Acid / Q000097:blood; D001424:Bacterial Infections / Q000097:blood* / Q000188:drug therapy* / Q000382:microbiology; D015415:Biomarkers / Q000097:blood; D003550:Cystic Fibrosis / Q000097:blood* / Q000188:drug therapy* / Q000382:microbiology; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D011379:Prognosis; D012008:Recurrence; D013183:Sputum / Q000382:microbiology; D018709:Statistics, Nonparametric; D016896:Treatment Outcome; D014810:Vitamin E / Q000097:blood*
D000900:Anti-Bacterial Agents; D000975:Antioxidants; D015415:Biomarkers; D014810:Vitamin E; D001205:Ascorbic Acid